Compare Toyota Motor Corp (TM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toyota Motor Corp vs Twist Bioscience Corp — how do they compare? Toyota Motor Corp trades at $184.95 (market cap $217.38B), while Twist Bioscience Corp trades at $161.08 (market cap $10.08B). The key difference: Toyota Motor Corp is far larger — about 21.6× Twist Bioscience Corp's market cap, and Toyota Motor Corp pays a 3.37% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toyota Motor Corp for 116 Days and Twist Bioscience Corp for 27 Days on average.
| TM | TWST | |
|---|---|---|
Market Cap | $217.38B | $10.08B |
Volume | 291,250 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $248.29 | $205.00 |
52-Week Low | $166.50 | $25.45 |
Typical Hold Time | 116 Days | 27 Days |
Enterprise Value | $410.96B | $10.01B |
Dividend Yield | 3.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Toyota Motor trades at $185.17, up 1.24% with a bearish technical signal despite strong fundamentals. The stock shows attractive valuation metrics with a P/E of 8.38 and P/S of 0.73, while delivering consistent earnings beats in recent quarters. Recent news highlights strong U.S. sales performance and electrification progress, though technical indicators show selling pressure with key support at $184.
Toyota presents a value opportunity with solid profitability and clean balance sheet, though near-term headwinds include China sales weakness and production disruptions. Analyst consensus leans cautious with 62.5% hold ratings, reflecting concerns about profit margin compression despite the company's market leadership and electrification investments.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
